CD19 t-haNK- IV Administration

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaNCT07125872IBRXPhase 2Recruiting2027-05-25Estimated
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366IBRXPhase 2Not yet recruiting2027-12Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.